Antifungal agents for common outpatient paediatric infections

Bortolussi, Robert; Martin, Susanna

doi:10.1093/pch/12.10.875

Cited by 10 publications

(12 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antifungals like griseofulvin, terbinafine and itraconazole can be used in children above 2 years of age to treat glabrous tinea infections. [ 134 135 136 ] Considering the safety aspects, fluconazole may be the preferred systemic antifungal in infants and children below 2 years of age. Secretion and distribution pattern of this drug is not dependent on sebum and directly diffuses into the skin.…”

Section: Discussionmentioning

confidence: 99%

Indian association of dermatologists, venereologists and leprologists (IADVL) task force against recalcitrant tinea (ITART) consensus on the management of glabrous tinea (INTACT)

Rengasamy

Shenoy

Dogra

et al. 2020

Indian Dermatol Online J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Indian association of dermatologists, venereologists and leprologists (IADVL) task force against recalcitrant tinea (ITART) consensus on the management of glabrous tinea (INTACT)

Rengasamy

Shenoy

Dogra

et al. 2020

Indian Dermatol Online J

View full text Add to dashboard Cite

“…Several official guidelines addressing the treatment of tinea capitis are available from various organizations. 4,12,17,18,20 Among these guidelines, the common recommendation is the use of systemic antifungals as first-line treatment for tinea capitis, with the use of a topical agent as an adjuvant to prevent the spread of fungal spores. 4,12,18,20 Since its introduction in 1958, griseofulvin has served as a commonly used treatment for tinea capitis, especially when the causative organism is M. canis.…”

Section: Tre Atment/manag Ementmentioning

confidence: 99%

“…4,12,17,18,20 Among these guidelines, the common recommendation is the use of systemic antifungals as first-line treatment for tinea capitis, with the use of a topical agent as an adjuvant to prevent the spread of fungal spores. 4,12,18,20 Since its introduction in 1958, griseofulvin has served as a commonly used treatment for tinea capitis, especially when the causative organism is M. canis. However, griseofulvin (U.S. FDA-approved for patients >2 years of age) is no longer available in several countries.…”

Section: Tre Atment/manag Ementmentioning

confidence: 99%

Tinea capitis: An update

Gupta

Friedlander

Simkovich

2022

Pediatric Dermatology

View full text Add to dashboard Cite

Tinea capitis is an important superficial infection and affects children globally. A literature review was conducted to identify recent findings and the current understanding of this fungal infection. Here, we highlight updates on important aspects of tinea capitis including advances in dermatophyte detection and diagnosis and comparing these new methods to more traditional techniques. Additionally, aspects of treating tinea capitis are discussed, including the importance of mycological confirmation and current means of treatment, and the treatment of asymptomatic carriers are reviewed. This review also examines the subject of laboratory monitoring of patients undergoing treatment with systemic antifungals; we discuss the opinions of prominent researchers and currently accepted guidelines. Lastly, we provide answers to several common questions that practitioners may encounter when treating a child with tinea capitis.

show abstract

“…Tinea capitis is the most common superficial fungal infection affecting children in North America. 1 Impacting primarily African American children between 3 and 9 years of age, tinea capitis has been estimated to affect 3% to 8% of school-aged children living in inner city centres. 2 Communities of low socioeconomic status and those living in overcrowded living conditions are at the greatest risk.…”

Section: Introductionmentioning

confidence: 99%